In an additional clinical trial of PARP inhibitors in melanoma, a phase I study (NCT00516802) of Olaparib combined with dacarbazine in patients with advanced solid tumors aimed to determine the optimal combination dose for phase II trials (Table 3). This evidence concerns the gene PARP1 and melanoma.